Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS.

Nat Commun. 2017 Jun 23;8:16007. doi: 10.1038/ncomms16007.

2.

Clarification to Prison Litigation Reform Act "Three Strikes" Rule.

Datta V, Michaels TM, Chamberlain JR.

J Am Acad Psychiatry Law. 2017 Jun;45(2):271-273. No abstract available.

PMID:
28619878
3.

Government Management of Accompanied Minors Held in the Custody of Immigration Authorities.

Armontrout JA, Chamberlain JR.

J Am Acad Psychiatry Law. 2017 Jun;45(2):269-271. No abstract available.

PMID:
28619877
4.

Progress toward Gene Therapy for Duchenne Muscular Dystrophy.

Chamberlain JR, Chamberlain JS.

Mol Ther. 2017 May 3;25(5):1125-1131. doi: 10.1016/j.ymthe.2017.02.019. Epub 2017 Apr 15. Review.

5.

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS.

Nat Commun. 2017 Feb 14;8:14454. doi: 10.1038/ncomms14454. Erratum in: Nat Commun. 2017 Jun 23;8:16007.

6.

Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Bisset DR, Stepniak-Konieczna EA, Zavaljevski M, Wei J, Carter GT, Weiss MD, Chamberlain JR.

Hum Mol Genet. 2015 Sep 1;24(17):4971-83. doi: 10.1093/hmg/ddv219. Epub 2015 Jun 16.

7.

Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells.

Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, Chamberlain JR, Chamberlain JS.

Mol Ther Methods Clin Dev. 2014;1. pii: 14038.

8.

Systemic RNAi delivery to the muscles of ROSA26 mice reduces lacZ expression.

Wei J, Chamberlain JR.

PLoS One. 2014 Aug 15;9(8):e102053. doi: 10.1371/journal.pone.0102053. eCollection 2014.

9.

Animal models of muscular dystrophy.

Ng R, Banks GB, Hall JK, Muir LA, Ramos JN, Wicki J, Odom GL, Konieczny P, Seto J, Chamberlain JR, Chamberlain JS.

Prog Mol Biol Transl Sci. 2012;105:83-111. doi: 10.1016/B978-0-12-394596-9.00004-4. Review.

10.

AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy.

Bortolanza S, Nonis A, Sanvito F, Maciotta S, Sitia G, Wei J, Torrente Y, Di Serio C, Chamberlain JR, Gabellini D.

Mol Ther. 2011 Nov;19(11):2055-64. doi: 10.1038/mt.2011.153. Epub 2011 Aug 9.

11.

On fixing broken muscle...fall seven times, stand up eight--Japanese proverb.

Carter GT, Han JJ, Chamberlain JR, Chamberlain JS.

Muscle Nerve. 2010 Jun;41(6):737-9. doi: 10.1002/mus.21704. No abstract available.

PMID:
20513100
12.

Aging with muscular dystrophy: pathophysiology and clinical management.

Carter GT, Weiss MD, Chamberlain JR, Han JJ, Abresch RT, Miró J, Jensen MP.

Phys Med Rehabil Clin N Am. 2010 May;21(2):429-50. doi: 10.1016/j.pmr.2009.12.001. Review.

PMID:
20494287
13.

Muscling in: Gene therapies for muscular dystrophy target RNA.

Chamberlain JR, Chamberlain JS.

Nat Med. 2010 Feb;16(2):170-1. doi: 10.1038/nm0210-170.

PMID:
20134472
14.

Therapy for neuromuscular disorders.

Arnett AL, Chamberlain JR, Chamberlain JS.

Curr Opin Genet Dev. 2009 Jun;19(3):290-7. doi: 10.1016/j.gde.2009.03.005. Epub 2009 May 4. Review.

PMID:
19411172
15.

Effects of training on suicide risk assessment.

McNiel DE, Fordwood SR, Weaver CM, Chamberlain JR, Hall SE, Binder RL.

Psychiatr Serv. 2008 Dec;59(12):1462-5. doi: 10.1176/appi.ps.59.12.1462.

PMID:
19033175
16.

Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin.

Banks GB, Combs AC, Chamberlain JR, Chamberlain JS.

Hum Mol Genet. 2008 Dec 15;17(24):3975-86. doi: 10.1093/hmg/ddn301. Epub 2008 Sep 16.

17.

Impact of clinical training on violence risk assessment.

McNiel DE, Chamberlain JR, Weaver CM, Hall SE, Fordwood SR, Binder RL.

Am J Psychiatry. 2008 Feb;165(2):195-200. doi: 10.1176/appi.ajp.2007.06081396. No abstract available.

PMID:
18245189
18.

Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.

Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, Byers PH, Russell DW.

Mol Ther. 2008 Jan;16(1):187-93. Epub 2007 Oct 23.

19.

Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium.

Kesisoglou F, Chamberlain JR, Schmiedlin-Ren P, Kaz A, Fleisher D, Roessler B, Zimmermann EM.

Mol Pharm. 2005 Nov-Dec;2(6):500-8.

PMID:
16323957
20.

Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM, Underwood RA, Song KM, Sussman M, Byers PH, Russell DW.

Science. 2004 Feb 20;303(5661):1198-201.

22.

5' processing of tRNA precursors can Be modulated by the human La antigen phosphoprotein.

Fan H, Goodier JL, Chamberlain JR, Engelke DR, Maraia RJ.

Mol Cell Biol. 1998 Jun;18(6):3201-11.

23.
24.

An RNase P RNA subunit mutation affects ribosomal RNA processing.

Chamberlain JR, Pagán-Ramos, Kindelberger DW, Engelke DR.

Nucleic Acids Res. 1996 Aug 15;24(16):3158-66.

25.

Eukaryotic nuclear RNase P: structures and functions.

Chamberlain JR, Tranguch AJ, Pagán-Ramos E, Engelke DR.

Prog Nucleic Acid Res Mol Biol. 1996;55:87-119. Review. No abstract available.

PMID:
8787607
26.

Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study.

Chamberlain JS, Chamberlain JR, Fenwick RG, Ward PA, Caskey CT, Dimnik LS, Bech-Hansen NT, Hoar DI, Richards S, Covone AE, Govanni R, Abbs S, Bentley DR, Bobrow M, Rysiecki G, Ray PN, Boileau C, Junien C, Boehm C, Venne VL, Fujmura FK, Spiga I, Ferrari M, Tedeschi S, Bakker E, Kneppers AL, van Ommen GJ, Jain K, Spector E, Crandall B, Kiuru A, Savontaus ML, Caskey CT, Chamberlain JS, Chamberlain JR, Rysiecki G.

JAMA. 1992 May 20;267(19):2609-15.

PMID:
1573747
27.

PCR analysis of dystrophin gene mutation and expression.

Chamberlain JS, Farwell NJ, Chamberlain JR, Cox GA, Caskey CT.

J Cell Biochem. 1991 Jul;46(3):255-9.

PMID:
1774226

Supplemental Content

Loading ...
Support Center